NCT00002333

Brief Summary

To compare the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone, zalcitabine (dideoxycytidine; ddC) alone, and both in combination, in patients discontinuing or unable to take zidovudine (AZT).

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
900

participants targeted

Target at P75+ for phase_2 hiv-infections

Geographic Reach
3 countries

47 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

February 1, 1995

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

ZalcitabineDrug Therapy, CombinationAcquired Immunodeficiency SyndromeAIDS-Related ComplexSaquinavirHIV Protease Inhibitors

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Concurrent Medication:
  • Allowed:
  • G-CSF and erythropoietin.
  • Prophylaxis or chronic suppression/maintenance therapy with dapsone, aerosolized pentamidine, isoniazid, rifampin, fluoroquinolones, pyrazinamide, ethambutol, fluconazole, itraconazole, acyclovir, clotrimazole, nystatin, trimethoprim/sulfamethoxazole, pyrimethamine, folic acid, sulfadiazine, clindamycin, and fansidar.
  • Concurrent Treatment:
  • Allowed:
  • Limited localized radiation therapy to the skin.
  • Patients must have:
  • Documented HIV infection.
  • CD4 count 50 - 300 cells/mm3.
  • Received prior AZT that has been discontinued at least 28 days prior to study entry.
  • No active opportunistic infection requiring immediate treatment.

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Signs or symptoms of peripheral neuropathy.
  • Malabsorption or inadequate oral intake (defined as unable to eat one or more meals daily because of chronic nausea, emesis, or abdominal/oral-esophageal discomfort.
  • Malignancy, visceral Kaposi's sarcoma, or lymphoma requiring systemic chemotherapy and/or radiotherapy within the next 48 weeks.
  • Any grade 3 or worse laboratory or clinical abnormality.
  • Inability to comply with protocol requirements.
  • Concurrent Medication:
  • Excluded:
  • Other antiretroviral drugs.
  • Experimental drugs.
  • Nephrotoxic or hepatotoxic drugs.
  • Drugs likely to cause peripheral neuropathy.
  • Antineoplastic agents.
  • Biologic response modifiers.
  • +18 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (47)

Kaiser Foundation Hosp

Harbor City, California, 90710, United States

Location

UCSD

La Jolla, California, 920930679, United States

Location

UCLA School of Medicine

Los Angeles, California, 900121973, United States

Location

CARE Ctr / UCLA Med Ctr

Los Angeles, California, 90095, United States

Location

UCD

Sacramento, California, 95817, United States

Location

UCSF - San Francisco Gen Hosp

San Francisco, California, 94110, United States

Location

Davies Med Ctr / c/o HIV Institute

San Francisco, California, 94114, United States

Location

Mount Zion Med Ctr / UCSF

San Francisco, California, 94115, United States

Location

San Francisco Veterans Administration Med Ctr

San Francisco, California, 94121, United States

Location

Pacific Oaks Med Group / Rsch & Scientific Investigation

Sherman Oaks, California, 91403, United States

Location

Sunnyvale Med Clinic

Sunnyvale, California, 94086, United States

Location

Harbor - UCLA Med Ctr

Torrance, California, 90505, United States

Location

Veterans Administration Med Ctr

Washington D.C., District of Columbia, 20422, United States

Location

Miami Veterans Administration Med Ctr

Miami, Florida, 33125, United States

Location

Univ of Miami Dept of Medicine

Miami, Florida, 33136, United States

Location

Stratogen of South Florida

Miami Beach, Florida, 33140, United States

Location

AIDS Research Consortium of Atlanta

Atlanta, Georgia, 30308, United States

Location

West Paces Clinical Research Incoporated

Atlanta, Georgia, 30327, United States

Location

Rush Presbyterian - Saint Luke's Med Ctr

Chicago, Illinois, 60612, United States

Location

Univ of Kansas School of Medicine

Wichita, Kansas, 67214, United States

Location

Tulane Univ Med School

New Orleans, Louisiana, 70112, United States

Location

New England Med Ctr

Boston, Massachusetts, 02111, United States

Location

Massachusetts Gen Hosp / Harvard Med School

Boston, Massachusetts, 02114, United States

Location

New England Deaconess Hosp

Boston, Massachusetts, 02215, United States

Location

Harper Hosp

Detroit, Michigan, 48201, United States

Location

Washington Univ School of Medicine

St Louis, Missouri, 63108, United States

Location

UMDNJ - New Jersey Med School / Cooper Hosp

Camden, New Jersey, 08103, United States

Location

UMDNJ - New Jersy Med School

Newark, New Jersey, 08103, United States

Location

Albany Med College

Albany, New York, 12208, United States

Location

Beth Israel Med Ctr

New York, New York, 10003, United States

Location

Saint Vincent's Hosp and Med Ctr

New York, New York, 10011, United States

Location

Harkness Pavilion

New York, New York, 10032, United States

Location

Ohio State Univ Hosp

Columbus, Ohio, 43210, United States

Location

Oregon Health Sciences Univ

Portland, Oregon, 97201, United States

Location

Thomas Jefferson Med College

Philadelphia, Pennsylvania, 19107, United States

Location

Graduate Hosp / Tuttleman Cancer Ctr

Philadelphia, Pennsylvania, 19146, United States

Location

Univ of Tennessee

Memphis, Tennessee, 38163, United States

Location

Oaklawn Physicians Group

Dallas, Texas, 75219, United States

Location

Univ TX Galveston Med Branch

Galveston, Texas, 775550882, United States

Location

Baylor College of Medicine

Houston, Texas, 77005, United States

Location

Univ of Washington / Harborview Med Ctr

Seattle, Washington, 98104, United States

Location

Southern Alberta HIV Clinic

Calgary, Alberta, Canada

Location

McMaster Univ Med Ctr

Hamilton, Ontario, Canada

Location

Sunnybrook Health Science Ctr

Toronto, Ontario, Canada

Location

Clinique Medicale L'Actuele

Montreal, Quebec, Canada

Location

Montreal Gen Hosp

Montreal, Quebec, Canada

Location

San Juan Veterans Administration Med Ctr

San Juan, 009275800, Puerto Rico

Location

Related Publications (1)

  • Revicki D, Swartz C. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir-zalcitabine therapy for advanced HIV-infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:113 (abstract no 266)

    BACKGROUND

MeSH Terms

Conditions

HIV InfectionsAcquired Immunodeficiency SyndromeAIDS-Related Complex

Interventions

SaquinavirZalcitabine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

IsoquinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsQuinolinesDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-RingDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesDideoxynucleosides

Study Design

Study Type
interventional
Phase
phase 2
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1995-02

Locations